CD4 and pneumocystosis: Nevertheless, recent data from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) cohort have demonstrated that both primary and secondary PJP prophylaxis can be safely withdrawn (or withheld) in virologically suppressed patients on ART and CD4+ counts of 100–200 cells/mL as the incidence of PJP in this population is low [55,56].